The Procter & Gamble Company (PG): ev to ebit, 10 filed years
EV/EBIT at The Procter & Gamble Company was 19.26x in FY2026, the newest filed year. Across the 7 computed years from FY2020 it ranged from 19.26x (FY2026) to 23.27x (FY2024), with a median of 21.21x.
Tonight's figure on the company page: 20.54x, at the close of 2026-10-15, recomputed 2026-10-15. The table is each filed year on its own terms, with the formula below; the current figure may use trailing twelve months or, where the explainer says so, a different denominator.
Year by year
| Fiscal year | EV/EBIT | Read from |
|---|---|---|
| FY2017 The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read. | n/a | 10-K, filed 2017-08-07 |
| FY2018 The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read. | n/a | 10-K, filed 2018-08-07 |
| FY2019 The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read. | n/a | 10-K, filed 2019-08-06 |
| FY2020 | 21.21x | 10-K, filed 2020-08-06 |
| FY2021 | 20.75x | 10-K, filed 2021-08-06 |
| FY2022 | 21.90x | 10-K, filed 2022-08-05 |
| FY2023 | 22.28x | 10-K, filed 2023-08-04 |
| FY2024 | 23.27x | 10-K, filed 2024-08-05 |
| FY2025 | 20.39x | 10-K, filed 2025-08-04 |
| FY2026 | 19.26x | 10-K, filed 2026-08-04 |
How each year is computed
(Close at fiscal year end x diluted shares + total debt - cash) / operating income
P/E, free cash flow yield and EV to EBIT set each filed year against the close on or within a week before that fiscal year's end. The price archive here is about five years deep, so older years of those three read n/a. Per-share figures and share counts are put on today's share count after a confirmed split, the basis the price archive is kept on.
Read further
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.